The initial wave of Generative AI excitement in the life sciences is meeting a sobering reality: the “Implementation Gauntlet.” While the potential for AI to revolutionize the DMTA cycle is undisputed, many organizations remain trapped in “Pilot Purgatory,” unable to scale individual successes into enterprise-wide impact. Our latest whitepaper, “From Hype to Implementation,” deconstructs this […]
From Hype To Implementation Read More »
Over the past year, we’ve seen a sea change in drug discovery — from the adoption of AI & advanced automation to changes in the funding landscape and talent space. In our State of Play: 2025 report, we lay it all out for you.
BioPharma State of Play: 2025 Read More »
2024 has been a year of exciting advancements at Aspen Biosciences, marked by the expansion of our Pipeline and PharmExchange platforms and the launch of innovative features designed to empower drug discovery efforts and to improve their capital efficiency. We’re thrilled to share some of the highlights: New Modules: New Features: Overall, these new modules
2024: Year In Review Read More »
Over the past 5 years, AI and ML have advanced significantly in the pharmaceutical industry. We explored Generative AI, like ChatGPT, for mining drug development pipeline information. Our whitepaper documents the state-of-the-art and assesses AI’s readiness for such tasks, using Foghorn Therapeutics as a case study.
Generative AI : ChatGPT Experiments Read More »
